Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
“Two key questions arise around the use of psilocybin in patients undergoing antidepressant treatment,” said Prof. Matthias Liechti, the principal investigator of the study. “First, for safety reasons, should a patient stop using antidepressants before receiving psilocybin? Second, if there is no safety risk, will the antidepressant reduce the patient’s response to psilocybin? These results indicate that psilocybin may be dosed during escitalopram treatment without apparent impact on the effect of psilocybin. Thus, the study answers the first question and provides a positive indication for the second.”
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
The patent titled: “Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine” is expected to provide protection into 2036. Patent families protecting KETABET™ under an exclusive worldwide license agreement with the National Health Research Institutes have also been issued in Taiwan.
Wesana Health Reports Q3 2021 Financial Results
Chad Bronstein, Executive Chairman of Wesana Health Commented: “The third quarter marked a number of important strategic developments for Wesana Health, including the PsyTech acquisition…”
COMPASS Pathways announces further positive results from phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression
Professor Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: “Our additional analyses underline the robustness of our findings that a single high dose of COMP360 psilocybin, given in conjunction with psychological support, led to a rapid and sustained response for many patients. This phase IIb study was designed to determine the optimal COMP360 dose for our phase III programme, evaluating safety and efficacy at the primary endpoint at week 3…”
Cybin Announces FDA Approval for Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin announced that the U.S. Food and Drug Administration has authorized an investigator-initiated randomized, placebo-controlled Phase 2 clinical trial evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress.
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Mydecine announced it has filed a full patent application covering multiple families of psilocin analogs. The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting.
